Beta Bionics, Inc. (BBNX) Cash & Equivalents (2023 - 2026)

Beta Bionics (BBNX) has 4 years of Cash & Equivalents data on file, last reported at $30.2 million in Q1 2026.

• Quarterly Cash & Equivalents fell 28.85% year-over-year to $30.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.2 million (down 28.85% YoY) and the FY2025 annual result came in at $31.6 million, up 3.76% from the prior year.
• Cash & Equivalents eased to $30.2 million in Q1 2026 per BBNX's latest filing, from $31.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $42.5 million in Q1 2025, with the low at $13.0 million in Q2 2024.
• Average Cash & Equivalents over 4 years is $28.7 million, with a median of $30.3 million recorded in 2024.
• Year-over-year, Cash & Equivalents soared 169.21% in 2025 and dropped 28.85% in 2026.
• Beta Bionics' Cash & Equivalents stood at $26.6 million in 2023, then increased by 14.55% to $30.4 million in 2024, then grew by 3.76% to $31.6 million in 2025, then retreated by 4.34% to $30.2 million in 2026.
• Business Quant data shows BBNX's Cash & Equivalents at $30.2 million in Q1 2026, $31.6 million in Q4 2025, and $38.5 million in Q3 2025.